Novel promoter elements for persistent gene expression
CA 2317934 A1 · Owner: Genzyme Corporation · Inventors: Yew, Nelson; Marshall, John; Armentano, Donna
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention is directed to novel promoter elements for the persistent expression of an operably linked transgene. In one aspect the promoter elements are derived from the cytomegalovirus intermediate early promoter (CMV). In particular embodiments of the invention an adenoviral vector or , plasmid comprising CMV-derived promoter elements are used to achieve presistent expression of a transgene in a target cell. The invention is also directed to enhancer elements which effectuate increased expression of a transgene operably linked to CMV-derived promoter elements. In one aspect the , enhancer elements are derived from the human albumin gene.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 15, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 15, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 15, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.